Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.

Banerji U, Sain N, Sharp SY, Valenti M, Asad Y, Ruddle R, Raynaud F, Walton M, Eccles SA, Judson I, Jackman AL, Workman P.

Cancer Chemother Pharmacol. 2018 Nov;82(5):911-912. doi: 10.1007/s00280-018-3674-9.

PMID:
30173339
2.

Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients.

van der Heijden JW, Oerlemans R, Dijkmans BA, Qi H, van der Laken CJ, Lems WF, Jackman AL, Kraan MC, Tak PP, Ratnam M, Jansen G.

Arthritis Rheum. 2009 Jan;60(1):12-21. doi: 10.1002/art.24219.

3.

Exploitation of the folate receptor in the management of cancer and inflammatory disease.

Leamon CP, Jackman AL.

Vitam Horm. 2008;79:203-33. doi: 10.1016/S0083-6729(08)00407-X. Review.

PMID:
18804696
4.

Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945.

Pillai RG, Forster M, Perumal M, Mitchell F, Leyton J, Aibgirhio FI, Golovko O, Jackman AL, Aboagye EO.

Cancer Res. 2008 May 15;68(10):3827-34. doi: 10.1158/0008-5472.CAN-08-0135.

5.

An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.

Banerji U, Sain N, Sharp SY, Valenti M, Asad Y, Ruddle R, Raynaud F, Walton M, Eccles SA, Judson I, Jackman AL, Workman P.

Cancer Chemother Pharmacol. 2008 Oct;62(5):769-78. doi: 10.1007/s00280-007-0662-x. Epub 2008 Jan 10. Erratum in: Cancer Chemother Pharmacol. 2018 Nov;82(5):911-912.

PMID:
18193424
6.

Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells.

Forster MD, Ormerod MG, Agarwal R, Kaye SB, Jackman AL.

Cytometry A. 2007 Nov;71(11):945-50.

7.

Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography.

Perumal M, Pillai RG, Barthel H, Leyton J, Latigo JR, Forster M, Mitchell F, Jackman AL, Aboagye EO.

Cancer Res. 2006 Sep 1;66(17):8558-64.

8.

Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.

Sain N, Krishnan B, Ormerod MG, De Rienzo A, Liu WM, Kaye SB, Workman P, Jackman AL.

Mol Cancer Ther. 2006 May;5(5):1197-208. Retraction in: Mol Cancer Ther. 2018 Sep;17(9):2075.

9.

Targeting the alpha-folate receptor with cyclopenta[g]quinazoline-based inhibitors of thymidylate synthase.

Henderson EA, Bavetsias V, Theti DS, Wilson SC, Clauss R, Jackman AL.

Bioorg Med Chem. 2006 Jul 15;14(14):5020-42. Epub 2006 Mar 22.

PMID:
16554160
10.

BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.

Gibbs DD, Theti DS, Wood N, Green M, Raynaud F, Valenti M, Forster MD, Mitchell F, Bavetsias V, Henderson E, Jackman AL.

Cancer Res. 2005 Dec 15;65(24):11721-8.

11.

A liquid chromatographic-tandem mass spectrometric method for the determination of two selective thymidylate synthase inhibitors, BGC945 and BGC638, in mouse plasma.

Wood N, Gibbs DD, Jackman AL, Henley A, Workman P, Raynaud F.

J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Sep 25;824(1-2):181-8.

PMID:
16061428
12.

Antifolates targeted specifically to the folate receptor.

Jackman AL, Theti DS, Gibbs DD.

Adv Drug Deliv Rev. 2004 Apr 29;56(8):1111-25. Review.

PMID:
15094210
13.
14.
15.

Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.

Farrugia DC, Ford HE, Cunningham D, Danenberg KD, Danenberg PV, Brabender J, McVicar AD, Aherne GW, Hardcastle A, McCarthy K, Jackman AL.

Clin Cancer Res. 2003 Feb;9(2):792-801.

16.

The design and synthesis of water-soluble analogues of CB30865, a quinazolin-4-one-based antitumor agent.

Bavetsias V, Skelton LA, Yafai F, Mitchell F, Wilson SC, Allan B, Jackman AL.

J Med Chem. 2002 Aug 15;45(17):3692-702.

PMID:
12166942
17.

A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours.

Jackman AL, Melin CJ, Kimbell R, Brunton L, Aherne GW, Theti DS, Walton M.

Biochim Biophys Acta. 2002 Jul 18;1587(2-3):215-23. Review.

19.

Cyclopenta[g]quinazoline-based antifolates: the effect of the chirality at the 6-position on the inhibition of thymidylate synthase (TS).

Bavetsias V, Marriott JH, Theti DS, Melin JC, Wilson SC, Jackman AL.

Bioorg Med Chem Lett. 2001 Dec 3;11(23):3015-7.

PMID:
11714600
20.

Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules.

Aherne GW, Hardcastle A, Ward E, Dobinson D, Crompton T, Valenti M, Brunton L, Jackman AL.

Clin Cancer Res. 2001 Sep;7(9):2923-30.

21.
22.

Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.

van der Wilt CL, Backus HH, Smid K, Comijn L, Veerman G, Wouters D, Voorn DA, Priest DG, Bunni MA, Mitchell F, Jackman AL, Jansen G, Peters GJ.

Cancer Res. 2001 May 1;61(9):3675-81.

23.
24.

Leucovorin rescue from raltitrexed (tomudex)-induced antiproliferative effects: in vitro cell line and in vivo mouse studies.

Farrugia DC, Aherne GW, Brunton L, Clarke SJ, Jackman AL.

Clin Cancer Res. 2000 Sep;6(9):3646-56.

26.

Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331.

Webley SD, Hardcastle A, Ladner RD, Jackman AL, Aherne GW.

Br J Cancer. 2000 Sep;83(6):792-9.

27.

Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues.

Welsh SJ, Titley J, Brunton L, Valenti M, Monaghan P, Jackman AL, Aherne GW.

Clin Cancer Res. 2000 Jun;6(6):2538-46.

28.

Design and synthesis of Cyclopenta[g]quinazoline-based antifolates as inhibitors of thymidylate synthase and potential antitumor agents(,).

Bavetsias V, Marriott JH, Melin C, Kimbell R, Matusiak ZS, Boyle FT, Jackman AL.

J Med Chem. 2000 May 18;43(10):1910-26.

PMID:
10821704
29.

Balb/c mice as a preclinical model for raltitrexed-induced gastrointestinal toxicity.

Clarke SJ, Farrugia DC, Aherne GW, Pritchard DM, Benstead J, Jackman AL.

Clin Cancer Res. 2000 Jan;6(1):285-96.

30.

Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations.

Jackman AL, Kimbell R, Ford HE.

Eur J Cancer. 1999 Mar;35 Suppl 1:S3-8. Review.

PMID:
10645207
31.

Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors.

Marsham PR, Wardleworth JM, Boyle FT, Hennequin LF, Kimbell R, Brown M, Jackman AL.

J Med Chem. 1999 Sep 23;42(19):3809-20.

PMID:
10508430
32.

A novel class of lipophilic quinazoline-based folic acid analogues: cytotoxic agents with a folate-independent locus.

Skelton LA, Ormerod MG, Titley J, Kimbell R, Brunton LA, Jackman AL.

Br J Cancer. 1999 Apr;79(11-12):1692-701.

33.

A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2.

Rohlff C, Watson SA, Morris TM, Skelton L, Jackman AL, Page MJ.

Cancer Res. 1999 Mar 15;59(6):1268-72.

34.

The renal effects of the water-soluble, non-folylpolyglutamate synthetase-dependent thymidylate synthase inhibitor ZD9331 in mice.

Walton MI, Mitchell F, Aherne GW, Medlow CJ, Boyle FT, Jackman AL.

Br J Cancer. 1998 Dec;78(11):1457-63.

36.

Nonpolyglutamatable antifolates as inhibitors of thymidylate synthase (TS) and potential antitumour agents.

Bavetsias V, Jackman AL.

Curr Med Chem. 1998 Aug;5(4):265-88. Review.

PMID:
9668195
37.

Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models.

Aherne GW, Ward E, Lawrence N, Dobinson D, Clarke SJ, Musgrove H, Sutcliffe F, Stephens T, Jackman AL.

Br J Cancer. 1998;77(2):221-6.

38.

Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.

Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, Smith MN, Wardleworth JM, Boyle FT.

Clin Cancer Res. 1997 Jun;3(6):911-21.

39.
40.
41.

Inhibition of thymidylate synthase: biochemical pharmacology of drugs with activity in colorectal cancer.

Jackman AL.

Tumori. 1997 Jan-Feb;83(1 Suppl):S65-6. Review. No abstract available.

PMID:
9154072
42.

Folate-based thymidylate synthase inhibitors in cancer chemotherapy.

Takemura Y, Jackman AL.

Anticancer Drugs. 1997 Jan;8(1):3-16. Review.

PMID:
9147608
43.

Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT).

Springer CJ, Bavetsias V, Jackman AL, Boyle FT, Marshall D, Pedley RB, Bisset GM.

Anticancer Drug Des. 1996 Dec;11(8):625-36.

PMID:
9022750
44.

Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs.

Takemura Y, Kobayashi H, Miyachi H, Gibson W, Kimbell R, Jackman AL.

Jpn J Cancer Res. 1996 Jul;87(7):773-80.

46.

Preclinical pharmacology of CB30900, a novel dipeptide inhibitor of thymidylate synthase, in mice.

Walton MI, Gibson W, Aherne GW, Lawrence N, Stephens TC, Smith MN, Jackman AL.

J Pharmacol Exp Ther. 1996 May;277(2):909-16.

PMID:
8627573
47.

Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.

Clarke SJ, Hanwell J, de Boer M, Planting A, Verweij J, Walker M, Smith R, Jackman AL, Hughes LR, Harrap KR, Kennealey GT, Judson IR.

J Clin Oncol. 1996 May;14(5):1495-503.

PMID:
8622063
48.

The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells.

Takemura Y, Kobayashi H, Gibson W, Kimbell R, Miyachi H, Jackman AL.

Int J Cancer. 1996 Mar 28;66(1):29-36.

49.

Quinazoline antifolates thymidylate synthase inhibitors: lipophilic analogues with modification to the C2-methyl substituent.

Hennequin LF, Boyle FT, Wardleworth JM, Marsham PR, Kimbell R, Jackman AL.

J Med Chem. 1996 Feb 2;39(3):695-704.

PMID:
8576912
50.

Supplemental Content

Loading ...
Support Center